Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Roberta Baltera, Stuart Collinson, Robert Millman

Premium

Arcturus Therapeutics has appointed Robert Baltera and Stuart Collinson to its board of directors.

Baltera previously served as CEO of Amira Pharmaceuticals, which was acquired by Bristol-Myers Squibb. Before that, he held various roles at Amgen. He is currently on the board of Organovo Holdings, Xencor, Panmira Pharmaceuticals, and San Diego Venture Group.

Collinson is a partner at investment firm Forward Ventures and is executive chairman of Tioga Pharmaceuticals. He previously was chairman, CEO, and president of Aurora Biosciences, which was acquired by Vertex. He has also held different senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International.


Tauriga Sciences has appointed Robert Millman to its business advisory board.

Millman is currently a managing director at MPM Capital and previously was chief intellectual property counsel for Alnylam Pharmaceuticals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.